Mumbai, India-based Glenmark Pharmaceuticals (NSE: GLENMARK) has received final approval from the US Food and Drug Administration (FDA) for its Olmesartan Medoxomil Tablets, a blood pressure treatment, the company reported on Friday.
The FDA has granted the drug approval in dose strengths of 5 mg, 20 mg and 40 mg. The drug is the generic equivalent of Benicar Tablets of Daiichi Sankyo Inc.
The Olmesartan Medoxomil tablets are set to be manufactured at the company's Goan production facility.
A statement by the company read: "Glenmark's current portfolio consists of 115 products authorised for distribution in the US marketplace and approximately 69 ANDAs pending approval with the US FDA.
"In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio."
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
International Isotopes Inc to change name to Radnostix Inc
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz
Padagis invests USD36m to expand manufacturing in Minneapolis
Newbury Pharmaceuticals gains Danish approval for generic ivermectin cream